Moneycontrol

Budget 2023Budget 2023

PARTNERS

  • Tata AIA Life Insurance
  • Hafele
  • Motilal Oswal
  • SMC Global Securities Limited
Upcoming Event : LeapToUnicorn - mentoring, networking and fundraising for startups. Register now
Budget 2023
Budget 2023

Bharat Biotech enters pact with GSK, PATH to produce, distribute malaria vaccine

As per the agreement GSK will transfer the manufacturing technology of the RTS,S antigens of the vaccine and will grant license on all rights pertaining to the RTS,S/AS01 malaria vaccine to Bharat Biotech. GSK will retain the production of the adjuvant of the vaccine (AS01E) and will supply it to Bharat Biotech.

January 27, 2021 / 06:28 PM IST

Bharat Biotech, UK drug giant GSK and US-based non-profit PATH on January 27 announced the signing of a product transfer agreement for the malaria vaccine.

As per the agreement, GSK will transfer the manufacturing technology of the RTS,S antigens of the vaccine and will grant license on all rights pertaining to the RTS,S/AS01 malaria vaccine to Bharat Biotech. GSK will retain the production of the adjuvant of the vaccine (AS01E) and supply it to Bharat Biotech.

The RTS,S/AS01E malaria vaccine, developed by GSK for more than 30 years, and in partnership with PATH since 2001, is currently being piloted in regions of Ghana, Kenya, and Malawi under the Malaria Vaccine Implementation Programme (MVIP).

"Ministries of health are leading the implementation of the vaccine, which is being given to young children through the three countries’ routine immunisation programmes, with WHO providing technical and scientific leadership, playing a coordinating role, and working in collaboration with GSK, PATH, and a range of other partners," Bharat Biotech said in a statement.